A phase II study of Bortezomib for relapsed/refractory adult T-cell leukemia/lymphoma (ATL).
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Bortezomib (Primary)
- Indications T-cell leukaemia
- Focus Therapeutic Use
- 13 Feb 2013 Planned End Date changed from 1 Mar 2013 to 31 Mar 2014 as reported by University Hospital Medical Information Network - Japan.
- 28 Sep 2011 New trial record